Ablukast (
INN) is an experimental drug that is a
leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease.[1][2] It reached Phase III clinical trials, but
development was discontinued in 1996.[2]
References
^Rosenbach T, Csatò M, Czarnetzki BM (January 1988). "Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis". The British Journal of Dermatology. 118 (1): 1–6.
doi:
10.1111/j.1365-2133.1988.tb01743.x.
PMID2829957.
S2CID1164113.